HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Delayed-Action Preparations

Subscribe to New Research on Delayed-Action Preparations

Dosage forms of a drug that act over a period of time by controlled-release processes or technology.

Also Known As:

Controlled-Release Preparations; Controlled Release Preparations; Controlled-Release Preparation; Delayed Action Preparations; Delayed-Action Preparation; Depot Preparation; Preparation, Controlled-Release; Preparations, Controlled-Release; Prolonged-Action Preparation; Sustained-Release Preparation; Timed Release Preparations; Timed-Release Preparation; Depot Preparations; Prolonged-Action Preparations; Sustained-Release Preparations; Timed-Release Preparations

Networked: 245 relevant articles (26 outcomes, 49 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	David, A: 11 articles (01/2007 - 01/2000)
2.	Quraishi, S: 9 articles (01/2005 - 01/2000)
3.	Adams, C E: 4 articles (01/2007 - 01/2000)
4.	Adams, Clive E: 3 articles (01/2015 - 01/2011)
5.	Purgato, Marianna: 2 articles (01/2012 - 01/2011)
6.	Biermasz, Nienke R: 2 articles (11/2005 - 03/2003)
7.	Roelfsema, Ferdinand: 2 articles (11/2005 - 03/2003)
8.	Romijn, Johannes A: 2 articles (11/2005 - 03/2003)
9.	Rathbone, J: 2 articles (01/2005 - 01/2005)
10.	Quraishi, S N: 2 articles (01/2004 - 01/2004)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/1992 - "Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. " 01/01/1995 - "[Aggravation of Parkinson's disease after inadequate use of levodopa in controlled-release preparations]." 10/30/1991 - "[Treatment of Parkinson disease with levodopa depot preparations]." 01/01/1986 - "Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations." 01/01/1987 - "The efficacy of a novel oral sustained-release preparation of L-dopa (Madopar HBS) was compared to that of previous standard L-dopa treatment in 10 patients with idiopathic Parkinson's disease and severe fluctuations in motor performance in an open inpatient trial. "
2.	Angina Pectoris 04/01/1999 - "The clinical efficacy of a combined immediate-release and sustained-release preparation of isosorbide-5-mononitrate for angina pectoris is observed within a few minutes of administration. " 09/01/1989 - "Twenty-four patients with severe stable angina pectoris were included in a randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of a controlled-release preparation of isosorbide-5-mononitrate (ISMN-CR) 60 mg once daily or twice daily as adjunctive treatment to a beta blocker. " 01/01/1989 - "The efficacy of a sustained-release preparation of verapamil (verapamil-SR) has been compared with that of a conventional instant-release formulation (verapamil-IR) in 10 patients with stable angina pectoris treated for 3 weeks with both preparations. " 01/01/1980 - "The antianginal action of a sustained-release preparation of isosorbide dinitrate (SUS-ID), administered twice a day, was examined in open trial in 61 patients with angina pectoris. " 02/01/1987 - "The effectiveness of a sustained-release preparation of verapamil (verapamil-SR) was compared with the regular formulation of verapamil and with placebo in 12 patients with chronic stable angina pectoris. "
3.	Pain (Aches) 01/01/2014 - "To address the problem of noncompliance, numerous studies have been carried out, involving: sustained-release preparations, prolonged half-life derivatives, new injectors that cause less pain, and other noninvasive delivery methods such as intranasal, pulmonary and transdermal deliveries. " 01/01/2015 - "It is a sustained release preparation of bupivacaine that has been shown to provide pain relief for up to 72 hours with a single local administration. " 02/01/1996 - "1. The aim of this study was to investigate the analgesic effect and its duration of a new sustained-release preparation of tramadol in an experimental pain model based on pain-related chemosomatosensory evoked potentials (CSSEPs) and subjective intensity estimates of painful phasic and tonic stimuli. " 02/01/1996 - "Dose dependent time course of the analgesic effect of a sustained-release preparation of tramadol on experimental phasic and tonic pain." 10/01/1994 - "Morphine remains the drug of choice for chronic pain when administered in a sustained release preparation. "
4.	Ulcerative Colitis 06/01/1994 - "Their main role remains as maintenance therapy for ulcerative colitis, but relatively high doses of controlled-release preparations benefit patients with ileal Crohn's disease, following resection, or those who have recently relapsed. " 11/01/1982 - "The sustained-release preparation studied provides sufficient amounts of 5-aminosalicylic acid to all parts of the gut and its curative effect in ulcerative colitis and Crohn's disease should be examined in controlled trials." 04/01/1996 - "1. A controlled-release preparation of mesalazine microgranules (PentasaR; Ferring AS, Vanlose, Denmark) releases the active ingredient over a wide area from the small intestine to the rectum and is consequently expected to bring about therapeutic benefits to patients with ulcerative colitis and Crohn's disease. " 01/01/2002 - "Methylprednisolone acetate as a depot preparation and oral prednisolone are equally effective in inducing remission in patients with moderately active ulcerative colitis. " 08/01/1994 - "Delivery of 5-aminosalicylic acid to the colon by sulphasalazine, other azo-bonded compounds and controlled-release preparations is introduced in the context of metabolism by epithelial cells and therapeutic efficacy in ulcerative colitis. "
5.	Precocious Puberty 07/01/2015 - "Depot preparations of gonadotropin-releasing hormone agonists (GnRHa) are the gold standard drugs for the treatment of central precocious puberty. " 09/01/2002 - "Our animal tests indicate strong potential for the development and testing of long-acting depot preparations of GnRH antagonists in treating precocious puberty." 01/01/2002 - "The efficacy of a 3-month depot preparation of the GnRH agonist leuprorelin acetate in central precocious puberty was studied. " 01/01/1993 - "Changes in growth hormone-binding protein in girls with central precocious puberty treated with a depot preparation of luteinizing hormone-releasing hormone analogue." 02/01/1990 - "A total of 82 patients (74 girls, 8 boys) are presently participating in an international multicentre trial for treatment of central precocious puberty (CPP) with a slow release gonadotropin-releasing hormone (GnRH) agonist depot preparation: Decapeptyl-Depot (DD). "

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Gonadotropin-Releasing Hormone (GnRH)
3.	levodopa drug combination benserazide
4.	Benserazide
5.	Methylphenidate (Ritalin)
6.	isosorbide-5-mononitrate (Ismo)
7.	Theophylline (Theon)
8.	Diltiazem (Cardizem)
9.	Leuprolide (Lupron)
10.	Mesalamine (Mesalazine)

Related Therapies and Procedures

1.	Orchiectomy (Orchidectomy)
2.	Injections
3.	Drug Therapy (Chemotherapy)
4.	Subcutaneous Infusions
5.	Intramuscular Injections